Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NAT1 | P18440 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | GPR39 | O43194 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26811062 | 0.88 | TSHR (0.45) | TSHRSMN1; SMN2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL26811113 | 0.87 | TSHR (0.43) | TSHRSMN1; SMN2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL26810953 | 0.86 | TSHR (0.48) | TSHRSMN1; SMN2MCL1CYP2C9CYP1A2 | |
| SCHEMBL26811084 | 0.85 | MAPT (0.50) | TSHRSMN1; SMN2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL26811087 | 0.84 | TSHR (0.46) | TSHRSMN1; SMN2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL26810957 | 0.84 | TSHR (0.54) | TSHRSMN1; SMN2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL26810785 | 0.84 | TSHR (0.48) | TSHRSMN1; SMN2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL26811070 | 0.83 | PLA2G7 (0.46) | TSHRSMN1; SMN2NAT1MAPTMEN1 | |
| SCHEMBL26811129 | 0.82 | MAPT (0.50) | TSHRSMN1; SMN2MCL1CYP2C9CYP1A2 | |
| SCHEMBL26806813 | 0.82 | MAPT (0.61) | TSHRSMN1; SMN2CYP2C9CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TSHR 1755/4885SMN1; SMN2 4847/4885MCL1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.